Could a stomach drug help fight pancreatic cancer?

NCT ID NCT05827055

Ongoing Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial investigates whether adding proglumide, a drug that blocks cholecystokinin receptors, to standard chemotherapy can improve treatment for metastatic pancreatic cancer. About 30 adults with advanced pancreatic cancer will receive either proglumide or a placebo alongside gemcitabine and nab-paclitaxel. The study aims to see if proglumide can safely reduce fibrosis in the tumor environment and potentially improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Proglumide
What this could lead to: If successful, this approach could offer a new way to make chemotherapy more effective for people with metastatic pancreatic cancer.
What could go wrong: This is a small, early-phase trial. The drug may not improve outcomes or could add side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC CANCER

Contacts and locations

Locations

Lombardi Comprehensive Cancer Center, Georgetown University

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.